JP2021516666A5 - - Google Patents
Info
- Publication number
- JP2021516666A5 JP2021516666A5 JP2020541595A JP2020541595A JP2021516666A5 JP 2021516666 A5 JP2021516666 A5 JP 2021516666A5 JP 2020541595 A JP2020541595 A JP 2020541595A JP 2020541595 A JP2020541595 A JP 2020541595A JP 2021516666 A5 JP2021516666 A5 JP 2021516666A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphocytes
- activated
- prostate cancer
- approximately
- myeloinfiltrating
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862646649P | 2018-03-22 | 2018-03-22 | |
| US62/646,649 | 2018-03-22 | ||
| PCT/US2019/023543 WO2019183455A1 (en) | 2018-03-22 | 2019-03-22 | Prostate cancer specific marrow infiltrating lymphocytes and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021516666A JP2021516666A (ja) | 2021-07-08 |
| JPWO2019183455A5 JPWO2019183455A5 (https=) | 2022-03-30 |
| JP2021516666A5 true JP2021516666A5 (https=) | 2022-03-30 |
Family
ID=67986362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541595A Pending JP2021516666A (ja) | 2018-03-22 | 2019-03-22 | 前立腺がん特異的髄浸潤リンパ球およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210000876A1 (https=) |
| EP (1) | EP3735256A4 (https=) |
| JP (1) | JP2021516666A (https=) |
| KR (1) | KR20200135936A (https=) |
| CN (1) | CN112074280A (https=) |
| AU (1) | AU2019240420A1 (https=) |
| CA (1) | CA3084179A1 (https=) |
| IL (1) | IL277482A (https=) |
| MX (1) | MX2020006131A (https=) |
| SG (1) | SG11202005200XA (https=) |
| WO (1) | WO2019183455A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9687510B2 (en) * | 2014-09-04 | 2017-06-27 | The Johns Hopkins University | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions |
| JP2022507113A (ja) * | 2018-11-05 | 2022-01-18 | ウィンドミル セラピューティクス インコーポレイテッド | クローン性の増大した骨髄浸潤リンパ球およびそれらの使用 |
| SG11202104637VA (en) * | 2018-11-30 | 2021-06-29 | Windmil Therapeutics Inc | MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY |
| WO2020198031A1 (en) * | 2019-03-22 | 2020-10-01 | Windmil Therapeutics Inc. | Lung cancer specific marrow infiltrating lymphocytes and uses thereof |
| US20230100744A1 (en) * | 2020-02-28 | 2023-03-30 | Windmil Therapeutics, Inc. | Methods for enriching marrow infiltrating lymphocytes ("mils"), compositions containing enriched mils, and methods of using enriched mils |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| WO2003057171A2 (en) | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US9687510B2 (en) | 2014-09-04 | 2017-06-27 | The Johns Hopkins University | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions |
| IL295224B2 (en) | 2015-05-28 | 2025-07-01 | Kite Pharma Inc | Methods of conditioning patients for t cell therapy |
| EP3320087A4 (en) | 2015-07-08 | 2019-01-23 | The Johns Hopkins University | BONE MARROW FILTRATION LYMPHOCYTES (MILS) AS A T-CELL SOURCE FOR CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPY |
| GB201608918D0 (en) * | 2016-05-20 | 2016-07-06 | Aslan Pharmaceuticals Pte Ltd | Method |
-
2019
- 2019-03-22 EP EP19770414.1A patent/EP3735256A4/en not_active Withdrawn
- 2019-03-22 AU AU2019240420A patent/AU2019240420A1/en not_active Abandoned
- 2019-03-22 WO PCT/US2019/023543 patent/WO2019183455A1/en not_active Ceased
- 2019-03-22 CN CN201980021186.XA patent/CN112074280A/zh active Pending
- 2019-03-22 KR KR1020207019974A patent/KR20200135936A/ko not_active Ceased
- 2019-03-22 MX MX2020006131A patent/MX2020006131A/es unknown
- 2019-03-22 SG SG11202005200XA patent/SG11202005200XA/en unknown
- 2019-03-22 JP JP2020541595A patent/JP2021516666A/ja active Pending
- 2019-03-22 US US16/982,906 patent/US20210000876A1/en not_active Abandoned
- 2019-03-22 CA CA3084179A patent/CA3084179A1/en active Pending
-
2020
- 2020-09-21 IL IL277482A patent/IL277482A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021516666A5 (https=) | ||
| US20230000919A1 (en) | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions | |
| Zuo et al. | Alarmin-painted exosomes elicit persistent antitumor immunity in large established tumors in mice | |
| Antonios et al. | Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma | |
| US11684659B2 (en) | Tumor cell vaccines | |
| Gorchakov et al. | Challenges and prospects of chimeric antigen receptor T-cell therapy for metastatic prostate cancer | |
| Trzonkowski et al. | First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+ CD25+ CD127− T regulatory cells | |
| Liu et al. | High-efficient generation of natural killer cells from peripheral blood with preferable cell vitality and enhanced cytotoxicity by combination of IL-2, IL-15 and IL-18 | |
| Lee et al. | Tumor-infiltrating lymphocytes in melanoma | |
| EP3773626B1 (en) | Use of histone modifiers to reprogram effector t cells | |
| RU2015138483A (ru) | Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток | |
| Zhang et al. | Highly proliferative and hypodifferentiated CAR-T cells targeting B7–H3 enhance antitumor activity against ovarian and triple-negative breast cancers | |
| Son et al. | Combination treatment with decitabine and ionizing radiation enhances tumor cells susceptibility of T cells | |
| Pan et al. | Donor T-cell-derived interleukin-22 promotes thymus regeneration and alleviates chronic graft-versus-host disease in murine allogeneic hematopoietic cell transplant | |
| LaCelle et al. | Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy | |
| Wu et al. | Natural killer cell therapy: the key to tackle the bottleneck of cell therapies against solid tumor? | |
| CA3200513A1 (en) | Tumor cell vaccines | |
| Zhu et al. | Aurovertin B sensitizes colorectal cancer cells to NK cell recognition and lysis | |
| Kim et al. | Antigen Cross-Presentation by Type-2 Innate Lymphoid Cells Facilitates the Activation of Antitumor CD8+ T Cells | |
| Obertopp et al. | Local Single-Dose Radiation Improves Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes | |
| JPWO2019183455A5 (https=) | ||
| Chu et al. | Coupling programmed cell death 1-positive tumor-infiltrating t cells with anti-programmed cell death 1 antibody improves the efficacy of adoptive T-cell therapy | |
| Teo et al. | Tumor infiltrating lymphocytes from acute myeloid leukemia marrow can be reverted to CD45RA+ central memory state by reactivation in SIP (Simulated Infective Protocol) | |
| Sarker et al. | Tumor-infiltrating lymphocyte therapy: therapeutic advances and prospects | |
| Marcu et al. | Therapeutic vaccine strategies to induce tumor-specific T-cell responses |